X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (2779) 2779
Book Review (629) 629
Publication (207) 207
Conference Proceeding (106) 106
Magazine Article (11) 11
Book Chapter (3) 3
Dissertation (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
pembrolizumab (2816) 2816
oncology (1550) 1550
nivolumab (1385) 1385
index medicus (1355) 1355
immunotherapy (1332) 1332
humans (939) 939
ipilimumab (836) 836
cancer (825) 825
melanoma (786) 786
chemotherapy (782) 782
open-label (593) 593
metastasis (514) 514
patients (487) 487
tumors (442) 442
docetaxel (441) 441
lung cancer (429) 429
female (410) 410
male (410) 410
care and treatment (406) 406
pd-1 (397) 397
pd-l1 (378) 378
immunology (376) 376
middle aged (375) 375
survival (371) 371
safety (355) 355
aged (348) 348
immune checkpoint (346) 346
apoptosis (337) 337
cancer therapies (334) 334
multicenter (334) 334
clinical trials (330) 330
therapy (311) 311
blockade (281) 281
metastases (281) 281
cell lung-cancer (275) 275
pd-1 protein (264) 264
metastatic melanoma (258) 258
programmed cell death 1 receptor - antagonists & inhibitors (253) 253
expression (246) 246
respiratory system (246) 246
research (241) 241
adult (239) 239
pd-l1 protein (235) 235
lymphocytes (233) 233
atezolizumab (229) 229
analysis (224) 224
antibodies, monoclonal - therapeutic use (222) 222
pd-1 blockade (221) 221
antineoplastic agents - therapeutic use (212) 212
lung cancer, non-small cell (212) 212
advanced melanoma (206) 206
immunotherapy - methods (206) 206
biomarkers (201) 201
treatment outcome (200) 200
mutation (199) 199
antibodies, monoclonal, humanized - therapeutic use (197) 197
melanoma - drug therapy (195) 195
prognosis (192) 192
drug therapy (191) 191
medical research (190) 190
cell death (189) 189
immune checkpoint inhibitors (187) 187
ligands (187) 187
aged, 80 and over (180) 180
checkpoint inhibitors (180) 180
immunohistochemistry (177) 177
anti-pd-1 (171) 171
medicine, research & experimental (170) 170
medicine & public health (163) 163
non-small cell lung cancer (162) 162
medical prognosis (159) 159
antibodies (155) 155
carcinoma (154) 154
antineoplastic agents, immunological - therapeutic use (153) 153
adverse events (151) 151
health aspects (151) 151
lung neoplasms - drug therapy (150) 150
review (144) 144
programmed cell death 1 receptor - immunology (143) 143
t-cells (143) 143
toxicity (143) 143
trial (141) 141
cytotoxicity (140) 140
pharmacology & pharmacy (140) 140
lymphocytes t (139) 139
nsclc (138) 138
usage (136) 136
antibody (134) 134
antibodies, monoclonal, humanized - adverse effects (133) 133
inhibitors (131) 131
carcinoma, non-small-cell lung - drug therapy (128) 128
antibodies, monoclonal - adverse effects (125) 125
case report (123) 123
development and progression (123) 123
untreated melanoma (123) 123
b7-h1 antigen - antagonists & inhibitors (119) 119
hematology (119) 119
solid tumors (119) 119
melanoma - pathology (117) 117
antigens (116) 116
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (2749) 2749
German (40) 40
French (39) 39
Korean (10) 10
Russian (7) 7
Spanish (7) 7
Japanese (3) 3
Czech (2) 2
Icelandic (1) 1
Italian (1) 1
Polish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Der Urologe. Ausg. A, ISSN 0340-2592, 01/2019, Volume 58, Issue 1, pp. 45 - 48
Journal Article
JOURNAL OF CLINICAL ONCOLOGY, ISSN 0732-183X, 04/2019, Volume 37, Issue 11, pp. 940 - 940
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 06/2018, Volume 36, Issue 17, pp. 1658 - 1667
Purpose We evaluated the combination of talimogene laherparepvec plus ipilimumab versus ipilimumab alone in patients with advanced melanoma in a phase II... 
ONCOLOGY | NIVOLUMAB | PEMBROLIZUMAB | Rapid Communications
Journal Article
Journal der Deutschen Dermatologischen Gesellschaft, ISSN 1610-0379, 11/2018, Volume 16, Issue 11, pp. 1376 - 1378
Journal Article
JNCCN Journal of the National Comprehensive Cancer Network, ISSN 1540-1405, 03/2016, Volume 14, Issue 3, pp. 255 - 264
These NCCN Guidelines Insights focus on recent updates in the 2016 NCCN Guidelines for Non-Small Cell Lung Cancer (NSCLC; Versions 1-4). These NCCN Guidelines... 
PEMBROLIZUMAB | ONCOLOGY | NIVOLUMAB | IMMUNOTHERAPY | SAFETY | DOCETAXEL
Journal Article
European Journal of Cancer, ISSN 0959-8049, 07/2019, Volume 116, pp. 178 - 181
Journal Article
European Journal of Cancer, ISSN 0959-8049, 05/2019, Volume 113, pp. 69 - 71
Journal Article
Multiple Sclerosis Journal, ISSN 1352-4585, 6/2019, Volume 25, Issue 7, pp. 1008 - 1009
Journal Article
Nature Reviews Clinical Oncology, ISSN 1759-4774, 02/2019, Volume 16, Issue 2, pp. 66 - 66
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 02/2018, Volume 36, Issue 4, pp. 383 - 390
Purpose Until recently, limited options existed for patients with advanced melanoma who experienced disease progression while receiving treatment with... 
METASTATIC MELANOMA | PEMBROLIZUMAB | THERAPY | ONCOLOGY | ACQUIRED-RESISTANCE | COMBINATION | IPILIMUMAB
Journal Article
International Journal of Dermatology, ISSN 0011-9059, 2018, Volume 58, Issue 6, pp. 739 - 741
Journal Article
Clinical and Experimental Dermatology, ISSN 0307-6938, 07/2019, Volume 44, Issue 5, pp. 570 - 573
Click here for the corresponding questions to this CME article. 
DERMATOLOGY | Radiation | Pembrolizumab
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 2018, Volume 36, Issue 14, pp. 1387 - 1388
Journal Article
Journal der Deutschen Dermatologischen Gesellschaft, ISSN 1610-0379, 11/2018, Volume 16, Issue 11, pp. 1376 - 1378
Journal Article
ANNALES DE DERMATOLOGIE ET DE VENEREOLOGIE, ISSN 0151-9638, 11/2018, Volume 145, Issue 11, pp. 645 - 648
Journal Article
Lancet Oncology, ISSN 1470-2045, 10/2017, Volume 18, Issue 10, pp. 1307 - 1316
Background: BRAF(V600E) mutation occurs in 1-2% of lung adenocarcinomas and acts as an oncogenic driver. Dabrafenib, alone or combined with trametinib, has... 
SURVIVAL | HARBORING BRAF MUTATIONS | 1ST-LINE TREATMENT | MULTICENTER | MELANOMA | PEMBROLIZUMAB | ONCOLOGY | CRIZOTINIB | MULTICOHORT | CHEMOTHERAPY | EGFR
Journal Article
American Journal of Clinical Oncology: Cancer Clinical Trials, ISSN 0277-3732, 11/2018, Volume 41, Issue 11, pp. 1083 - 1088
Journal Article
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.